Skip to Main Content

Advertisement intended for health care professionals

Close

ASH Clinical News
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International
ASH
- ASH Home
- Research
- Education
- Advocacy
- Meetings
- Publications
- ASH Store

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current Issue
- All Issues
First edition
Abstracts
Collections
Author Center
About

Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 133, Issue 14

April 4 2019

In this Issue

BLOOD COMMENTARIES
PLENARY PAPER
BLOOD SPOTLIGHT
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
VASCULAR BIOLOGY
LETTER TO BLOOD
BLOOD WORK

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS

Should young adults with ALL be treated as children?
Clinical Trials & Observations

Hervé Dombret,Nicolas Boissel

View Articletitled, Should young adults with ALL be treated as children?

VASCULAR BIOLOGY

Ponatinib and platelets a conflict in CML

François Guilhot

View Articletitled, Ponatinib and platelets a conflict in CML

PLENARY PAPER

THROMBOSIS AND HEMOSTASIS

The von Willebrand factor D′D3 assembly and structural principles for factor VIII binding and concatemer biogenesis

Xianchi Dong,Nina C. Leksa,Ekta Seth Chhabra,Joseph W. Arndt,Qi Lu,Kevin E. Knockenhauer,Robert T. Peters,Timothy A. Springer

View Articletitled, The von Willebrand factor D′D3 assembly and structural principles for factor VIII binding and concatemer biogenesis

Supplemental data

BLOOD SPOTLIGHT

Myeloma bone disease: from biology findings to treatment approaches
Clinical Trials & Observations

Evangelos Terpos,Ioannis Ntanasis-Stathopoulos,Meletios A. Dimopoulos

View Articletitled, Myeloma bone disease: from biology findings to treatment approaches

HOW I TREAT

How I treat early-relapsing follicular lymphoma
Clinical Trials & Observations

Carla Casulo,Paul M. Barr

View Articletitled, How I treat early-relapsing follicular lymphoma

CLINICAL TRIALS AND OBSERVATIONS

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Clinical Trials & Observations

Wendy Stock,Selina M. Luger,Anjali S. Advani,Jun Yin,Richard C. Harvey,Charles G. Mullighan,Cheryl L. Willman,Noreen Fulton,Kristina M. Laumann,Greg Malnassy,Elisabeth Paietta,Edy Parker,Susan Geyer,Krzysztof Mrózek,Clara D. Bloomfield,Ben Sanford,Guido Marcucci,Michaela Liedtke,David F. Claxton,Matthew C. Foster,Jeffrey A. Bogart,John C. Grecula,Frederick R. Appelbaum,Harry Erba,Mark R. Litzow,Martin S. Tallman,Richard M. Stone,Richard A. Larson

View Articletitled, A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

HEMATOPOIESIS AND STEM CELLS

The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination

Ryan Donaghy,Xu Han,Krasimira Rozenova,Kaosheng Lv,Qinqin Jiang,Miriam Doepner,Roger A. Greenberg,Wei Tong

View Articletitled, The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination

Supplemental data

LYMPHOID NEOPLASIA

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

Junling Zhuang,Fazal Shirazi,Ram Kumar Singh,Isere Kuiatse,Hua Wang,Hans C. Lee,Zuzana Berkova,Allison Berger,Marc Hyer,Nibedita Chattopadhyay,Sakeena Syed,Judy Qiuju Shi,Jie Yu,Vaishali Shinde,Stephen Tirrell,Richard Julian Jones,Zhiqiang Wang,R. Eric Davis,Robert Z. Orlowski

View Articletitled, Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

Supplemental data

THROMBOSIS AND HEMOSTASIS

Increased galactose expression and enhanced clearance in patients with low von Willebrand factor

Sonia Aguila,Michelle Lavin,Niall Dalton,Sean Patmore,Alain Chion,George D. Trahan,Kenneth L. Jones,Catriona Keenan,Teresa M. Brophy,Niamh M. O’Connell,Kevin Ryan,Mary Byrne,Margaret Nolan,Anjali Patel,Roger J. S. Preston,Paula James,Jorge Di Paola,Jamie M. O’Sullivan,James S. O’Donnell

View Articletitled, Increased galactose expression and enhanced clearance in patients with low von Willebrand factor

Supplemental data

VASCULAR BIOLOGY

Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib

Yllka Latifi,Federico Moccetti,Melinda Wu,Aris Xie,William Packwood,Yue Qi,Koya Ozawa,Weihui Shentu,Eran Brown,Toshiaki Shirai,Owen J. McCarty,Zaverio Ruggeri,Javid Moslehi,Junmei Chen,Brian J. Druker,Jose A. López,Jonathan R. Lindner

There is a Blood Commentary on this article in this issue.

View Articletitled, Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib

Supplemental data

LETTER TO BLOOD

Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms

Gaurav Goyal,Denise Lau,Alison M. Nagle,Robert Vassallo,Karen L. Rech,Jay H. Ryu,Caroline J. Davidge-Pitts,W. Oliver Tobin,Matthew J. Koster,N. Nora Bennani,Mithun V. Shah,Minetta C. Liu,Ronald S. Go,on behalf of the Mayo Clinic Histiocytosis Working Group

View Articletitled, Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms

Supplemental data

BLOOD WORK

Biphenotypic plasma cell myeloma

Habibe Kurt,Karen A. Ferreira

View Articletitled, Biphenotypic plasma cell myeloma

Contamination

Jonathan Bloch,Sabine Blum

View Articletitled, Contamination

Cover Image

Cover Image

Confocal microscopy image of human umbilical vein endothelial cells stained for CD31 (green), von Willebrand factor (VWF, red), and nuclei (blue) in a microfluidic chamber illustrating surface expression of VWF after 24-hour exposure to the BCR-ABL tyrosine kinase inhibitor ponatinib. See the article by Latifi et al on page 1597.
Front Matter
Table of Contents
Back Matter
Editorial Board

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Chronic graft-versus-host disease: Unresolved complication or ancient history?

Aptamer BT200 blocks interaction of K1405-1408 in the VWF-A1 domain with macrophage LRP1

Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation - a National Multicenter Study

Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence

Blood coagulation factor IX: structural insights impacting hemophilia B therapy

Advertisement intended for health care professionals

Advertisement intended for health care professionals

Current Issue
First edition
All Issues

Collections
Abstracts
Authors

Submit to Blood
About Blood
Subscriptions

Public Access
Permissions
Alerts

Contact Us
Newsroom
Blood Classifieds

Advertising in Blood
Terms and Conditions
Twitter

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Neoplasia
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store

Copyright 2024 by American Society of Hematology

Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Advertisement intended for health care professionals